Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-0-30-253-8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$37.14 million
Profitability
Miscellaneous
Employees98
Next Earnings Date12/26/2019 (Estimated)
OptionableNot Optionable
Merus (NASDAQ:MRUS) Frequently Asked Questions
What is Merus' stock symbol?
Merus trades on the NASDAQ under the ticker symbol "MRUS."
How were Merus' earnings last quarter?
Merus NV (NASDAQ:MRUS) announced its quarterly earnings results on Thursday, May, 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.22. The biotechnology company earned $8.75 million during the quarter, compared to the consensus estimate of $7.47 million. Merus had a negative net margin of 104.10% and a negative return on equity of 40.08%. View Merus' Earnings History.
When is Merus' next earnings date?
What price target have analysts set for MRUS?
6 analysts have issued 1 year target prices for Merus' stock. Their predictions range from $16.00 to $35.00. On average, they expect Merus' stock price to reach $24.00 in the next year. This suggests a possible upside of 33.3% from the stock's current price. View Analyst Price Targets for Merus.
What is the consensus analysts' recommendation for Merus?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Merus.
Has Merus been receiving favorable news coverage?
Media stories about MRUS stock have been trending positive on Thursday, InfoTrie reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Merus earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for Merus.
Are investors shorting Merus?
Merus saw a decline in short interest in the month of July. As of July 15th, there was short interest totalling 305,000 shares, a decline of 5.9% from the June 15th total of 324,000 shares. Based on an average daily volume of 24,400 shares, the days-to-cover ratio is currently 12.5 days. Currently, 3.0% of the company's shares are sold short. View Merus' Current Options Chain.
Who are some of Merus' key competitors?
Some companies that are related to Merus include Prestige Consumer Healthcare (PBH), Nabriva Therapeutics (NBRV), Eidos Therapeutics (EIDX), Pacira Biosciences (PCRX), Insmed (INSM), Corcept Therapeutics (CORT), Turning Point Therapeutics (TPTX), Heron Therapeutics (HRTX), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Enanta Pharmaceuticals (ENTA), Ra Pharmaceuticals (RARX), Ironwood Pharmaceuticals (IRWD), Deciphera Pharmaceuticals (DCPH) and G1 Therapeutics (GTHX).
What other stocks do shareholders of Merus own?
Who are Merus' key executives?
Merus' management team includes the folowing people:
- Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
- Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
- Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
- Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
- Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)
When did Merus IPO?
(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Who are Merus' major shareholders?
Merus' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Novo Holdings A S (2.18%), Artal Group S.A. (1.54%), Morgan Stanley (0.41%), Athanor Capital LP (0.10%), Granite Investment Partners LLC (0.07%) and JPMorgan Chase & Co. (0.04%).
Which institutional investors are selling Merus stock?
MRUS stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC and Novo Holdings A S.
Which institutional investors are buying Merus stock?
MRUS stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Athanor Capital LP, JPMorgan Chase & Co. and Morgan Stanley.
How do I buy shares of Merus?
Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus' stock price today?
One share of MRUS stock can currently be purchased for approximately $18.00.
How big of a company is Merus?
Merus has a market capitalization of $409.52 million and generates $37.14 million in revenue each year. The biotechnology company earns $-28,660,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Merus employs 98 workers across the globe.View Additional Information About Merus.
What is Merus' official website?
How can I contact Merus?
Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]
MarketBeat Community Rating for Merus (NASDAQ MRUS)
MarketBeat's community ratings are surveys of what our community members think about Merus and other stocks. Vote "Outperform" if you believe MRUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
